Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children  by De la Cruz-Mosso, Ulises et al.
JO
B
4
c
U
A
J
a
b
d
c
d
G
R
A
J
c
0
h Pediatr (Rio J). 2013;89(5):492--498
www.jped.com.br
RIGINAL ARTICLE
ody  adiposity  but  not  insulin  resistance  is  associated  with -675
G/5G polymorphism  in the PAI-1  gene  in  a sample  of Mexican
hildren
lises De la Cruz-Mossoa, José Francisco Mun˜oz-Valleb,
ralia Berenice Salgado-Bernabéa, Natividad Castro-Alarcónc, Lorenzo Salgado-Goytiac,
osé  Sánchez-Coronad, Silvia Esperanza Flores-Martínezd, Isela Parra-Rojasc,∗
BSc.  Unidad  Académica  de  Ciencias  Químico  Biológicas,  Universidad  Autónoma  de  Guerrero,  Chilpancingo,  Guerrero,  Mexico
PhD.  Instituto  de  Investigación  en  Ciencias  Biomédicas,  Departamento  de  Biología  Molecular  y  Genómica,  Centro  Universitario
e Ciencias  de  la  Salud,  Universidad  de  Guadalajara,  Guadalajara,  Jalisco,  Mexico
PhD.  Unidad  Académica  de  Ciencias  Químico  Biológicas,  Universidad  Autónoma  de  Guerrero,  Chilpancingo,  Guerrero,  Mexico
PhD.  División  de  Medicina  Molecular,  Centro  de  Investigación  Biomédica  de  Occidente,  Instituto  Mexicano  del  Seguro  Social,
uadalajara, Jalisco,  Mexico
eceived 1  October  2012;  accepted  10  January  2013
vailable  online  18  July  2013
KEYWORDS
PAI-1  gene;
Polymorphisms;
Body  adiposity;
Insulin  resistance
Abstract
Objective:  To  assess  whether  the  -675  4G/5G  polymorphism  in  the  plasminogen  activator
inhibitor-1 gene  is  associated  with  obesity  and  insulin  resistance  in  Mexican  children.
Methods: A  cross-sectional  study  was  performed  in  174  children,  89  with  normal-weight  and  85
with  obesity,  aged  from  6  to  13  years.  All  children  were  from  state  of  Guerrero,  and  recruited
from  three  primary  schools  in  the  city  of  Chilpancingo,  state  of  Guerrero,  Mexico.  Insulin  levels
were  determined  by  immunoenzymatic  assay.  The  homeostasis  model  assessment  was  used  to
determine  insulin  resistance.  The  -675  4G/5G  polymorphism  in  PAI-1  gene  was  analyzed  by
polymerase  chain  reaction-restriction  fragment  length  polymorphism.
Results:  The  prevalence  of  insulin  resistance  in  the  obese  group  was  higher  (49.41%)  than  in
the  normal-weight  group  (16.85%).  The  4G/5G  PAI-1  polymorphism  was  found  in  Hardy  Wein-
berg  equilibrium.  The  4G/5G  genotype  contributed  to  a  signiﬁcant  increase  in  waist-hip  ratio
(  =  0.02,  p  =  0.006),  waist  circumference  (  =  4.42,  p  =  0.009),  and  subscapular  skinfold  thick-
ness  (  =  1.79,  p  =  0.04);  however,  it  was  not  related  with  insulin  resistance.
Conclusion:  The  -675  4G/5G  genotype  of  PAI-1  gene  was  associated  with  increase  of  body
adiposity in  Mexican  children.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.
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PALAVRAS-CHAVE
Gene  PAI-1;
Polimorﬁsmos;
Adiposidade  corporal;
Resistência insulínica
Adiposidade  corporal,  mas  não  resistência  insulínica,  associa-se  ao  polimorﬁsmo  -675
4G/5G  no  gene  PAI-1  em  uma  amostra  de  crianc¸as  mexicanas
Resumo
Objetivo:  Elaboramos  este  estudo  para  avaliar  se  o  polimorﬁsmo  -675  4G/5G  no  gene  inibidor
1 do  ativador  do  plasminogênio  se  associa  à  obesidade  e  à  resistência  insulínica  em  crianc¸as
mexicanas.
Métodos: Foi  realizado  um  estudo  transversal  em  174  crianc¸as,  89  delas  com  peso  normal  e
85 obesas,  variando  sua  idade  de  6  a  13  anos.  Todas  as  crianc¸as  eram  do  estado  de  Guerrero
e foram  recrutadas  de  três  escolas  primárias  na  cidade  de  Chilpancingo,  México.  Os  níveis  de
insulina  foram  determinados  por  prova  imunoenzimática.  Foi  usado  o  modelo  de  avaliac¸ão  da
homeostase  para  determinar  resistência  insulínica.  O  polimorﬁsmo  -675  4G/5G  no  gene  PAI-1
foi  analisado  pelo  método  reac¸ão  de  polimerase  em  cadeia-polimorﬁsmo  no  comprimento  dos
fragmentos  de  restric¸ão.
Resultados: A  prevalência  de  resistência  insulínica  no  grupo  obeso  foi  mais  alta  (49,41%)  do
que no  grupo  com  peso  normal  (16,85%).  O  polimorﬁsmo  4G/5G  do  PAI-1  foi  encontrado  em
equilíbrio  de  Hardy  Weinberg.  O  genótipo  4G/5G  contribuiu  para  um  aumento  signiﬁcativo  da
relac¸ão  cintura-quadril  (  =  0,02,  p  =  0,006),  da  circunferência  da  cintura  (  =  4,42,  p  =  0,009)  e
da  espessura  da  prega  subescapular  (  =  1,79,  p  =  0,04),  mas  não  se  relacionou  com  a  resistência
insulínica.
Conclusão: O  genótipo  -675  4G/5G  do  gene  PAI-1  se  associou  a  aumento  da  adiposidade  corporal
em crianc¸as  mexicanas.
© 2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Obesity  is  a  complex,  multifactorial  chronic  disease,  fre-
quently associated  with  insulin  resistance,  that  appears  to
be the  central  characteristic  to  the  pathogenesis  of  dia-
betes mellitus  type  2;  these  metabolic  disorders  have  been
associated with  increased  plasminogen  activator  inhibitor-1
(PAI-1) levels  in  circulation.1
PAI-1  is  the  main  inhibitor  in  the  plasminogen  activa-
tion system  (PAS),  which  comprises  an  inactive  proenzyme
(plasminogen) that  can  be  converted  into  its  active  form
plasmin by  the  action  of  physiological  plasminogen  acti-
vators (PAs).2 Plasmin  is  the  main  enzyme  that  degrades
ﬁbrin into  soluble  products.  Under  physiological  conditions
PAI-1, is  released  into  the  circulation  and  into  the  extracel-
lular space  by  certain  cells,  such  as  hepatocytes,  smooth
muscle cells,  spleen  cells,  myocytes,  adipocytes,  mono-
cytes, macrophages,  and  platelets,  which  are  the  main
source of  PAI-1.3--5 In  pathological  conditions,  other  tissues,
such as  tumor  and  endothelial  cells  secrete  a  large  amount
of PAI-1,  mainly  in  response  to  upregulation  by  inﬂamma-
tory cytokines;  thus,  PAI-1  is  regarded  as  a  marker  in  the
course of  inﬂammatory  processes.3,6,7 The  increase  of  PAI-1
levels in  plasma  is  associated  with  risk  factors  such  as  obe-
sity, glucose  intolerance,  hypertension,  insulin  resistance,
and metabolic  syndrome.4,8--10
Over  180  single  nucleotide  polymorphisms  (SNPs)  have
been described  in  the  PAI-1  gene.  The  -675  4G/5G  polymor-
phism is  characterized  by  an  insertion/deletion  of  a  single
nucleotide guanine  at  position  -675  of  the  promoter  of  PAI-
1 gene.11 This  polymorphism  has  been  associated  with  high
levels of  PAI-1,  obesity,  hypertension,  dyslipidemia,  glucose
intolerance, and  insulin  resistance.12 In  a  white  European
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aopulation  it  has  been  reported  that  subjects  who  are
omozygous for  the  4G  allele  (4G/4G  genotype)  have  plasma
oncentrations of  PAI-1  approximately  25%  higher  than  sub-
ects who  are  homozygous  for  the  5G  allele  (genotype
G/5G).11 In  another  study,  the  -675  4G/5G  polymorphism
nﬂuenced the  development  of  a state  of  insulin  resis-
ance and  obesity,  indicating  that  this  polymorphism  may
e a  marker  of  genetic  susceptibility  for  these  diseases.1,12
herefore,  this  study  was  designed  to  assess  whether  the
675 4G/5G  PAI-1  gene  polymorphism  is  associated  with  obe-
ity and  insulin  resistance  in  Mexican  children.
ethods
 cross-sectional  study  was  performed  in  174  children,  89
ith normal  weight  and  85  with  obesity,  aged  between  6
nd 13  years.  All  children  were  from  the  state  of  Guerrero,
exico, and  recruited  from  three  primary  schools  in  the  city
f Chilpancingo,  Mexico.  An  informed  consent  was  obtained
rom all  parents  before  enrollment  of  children  in  the  study.
pproval for  the  study  was  obtained  from  the  Research
thics Committee  of  the  University  of  Guerrero  according
o the  ethical  guidelines  of  the  Declaration  of  Helsinki.
Body  weight  was  determined  using  a  Tanita  body  compo-
ition monitor  (Tanita  BC-553  =  Arlington,  USA),  and  height
as measured  to  the  nearest  0.1  cm  using  a  stadiometer
Seca - Hamburg,  Germany).  Body  circumferences  were
easured in  duplicate  using  a  diameter  tape  accurate  to
ithin ±  0.1  cm  (Seca  201  -  Hamburg,  Germany).  Waist  cir-
umference was  measured  at  the  level  of  the  umbilicus  and
he superior  iliac  crest.  Hip  circumference  was  measured
t the  maximum  point  below  the  waist,  without  compressing
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Figure  1  Panel  A.  Polyacrylamide  gel  electrophoresis  showing  polymerase  chain  reaction  ampliﬁcation  of  99  pb  fragment  of  -675
4G/5G  polymorphism.  Lane  1:  50  bp  DNA  ladder;  lanes  2,  3,  and  4  PCR  product  98-99  bp.  Panel  B.  Polyacrylamide  gel  electrophoresis
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showing pattern  restriction  of  -675  4G/5G  polymorphism.  Lane
NA  ladder;  lane  5:  4G/4G  genotype.
he  skin.  The  thickness  of  four  skinfolds  was  measured  to  the
earest 0.1  mm,  in  duplicate,  using  a  skinfold  caliper  (Dyna-
ronics Co  -  Salt  Lake  City,  USA):  triceps,  biceps,  subscapular,
nd suprailiac.  The  duplicate  measures  were  averaged.  The
lassiﬁcation of  obesity  was  made  using  the  2000  Centers  for
isease Control  and  Prevention  growth  charts,  which  deﬁned
ormal weight  as  the  5th  to  85th  percentiles,  and  obesity  as
 95th  percentile.
Blood samples  were  obtained  from  antecubital  venipunc-
ure after  overnight  fast.  Serum  glucose  was  analyzed  with
emi-automated equipment  (COBAS  MIRA).  Insulin  levels
ere determined  by  immunoenzymatic  assay  (GenWay  INS-
ASIA kit).  The  homeostasis  model  assessment  was  used  to
etermine insulin  resistance  (IR)  in  children;  this  score  was
alculated with  the  following  formula:  fasting  serum  insulin
U/mL) x  fasting  plasma  glucose  (mmol/L)/22.5.  Insulin
esistance was  deﬁned  as  a  homeostasis  model  assessment
or insulin  resistance  (HOMA-IR)  above  the  75th  percentile
or all  children  (HOMA-IR  ≥  2.4).
The  extraction  of  genomic  DNA  (gDNA)  was  per-
ormed from  leukocytes  obtained  from  whole  blood
amples, according  to  the  Miller  method.  The  -675
G/5G PAI-1  gene  polymorphism  was  screened  by  the
olymerase chain  reaction-restriction  fragment  length
olymorphism (PCR-RFLP)  method,  using  following
rimers: 5′CACAGAGAGAGTCTGGCCACGT3′ (forward),
nd 5′CCAACAGAGGACTCTTGGTCT3′ (reverse).  PCR  was
arried out  in  a  ﬁnal  volume  of  25  L  containing  1  g  of
NA, 0.06  M  of  each  oligonucleotide,  1.25  U/L  Taq  DNA
olymerase, supplied  buffer  enzyme  1X,  1.5  mM  MgCl2,
nd 0.1  mM  of  each  dNTP  (InvitrogenTM life  technologies).
CR was  performed  by  initial  denaturation  at  94 ◦C  during
 min,  30  cycles  of  ampliﬁcation  at  94 ◦C  during  30  s  for
enaturation, at  60 ◦C  during  30  s for  annealing,  and  at
2 ◦C  during  30  s  for  extension.  Finally,  72 ◦C  during  1  min
as used  for  end  extension,  resulting  in  a  fragment  of  99  bp
or the  5G  or  98  bp  for  the  4G.  These  were  analyzed  on  a  6%
olyacrylamide gel  (InvitrogenTM life  technologies)  stained
o
d
t
tG/5G  genotype;  lanes  2  and  4:  5G/5G  genotype;  lane  3:  50  bp
ith  silver  nitrate.  Ampliﬁed  fragments  were  digested  for
 h  and  30  min  at  55 ◦C  with  3  U  of  Bsl  I (New  England  Bio-
abs) restriction  enzyme.  Afterwards,  restriction  fragments
ere analyzed  by  electrophoresis  on  6%  polyacrylamide
el (InvitrogenTM life  technologies)  stained  with  silver
itrate. PAI-1  genotyping  was  done  in  duplicate  in  all  cases
Fig. 1).  To  conﬁrm  the  results,  were  random  selected  a
ew genotypes  and  analyzed  for  sequencing.
The  statistical  analysis  was  performed  using  the
tatistical software  STATA  v.  9.2.  For  the  descriptive  anal-
sis, nominal  variables  were  expressed  as  frequencies,
ontinuous variables  normally-distributed  as  mean  and
tandard deviation,  and  those  not  normally-distributed  were
xpressed  as  medians  and  5th  and  95th  percentiles.  The
hi-squared test  was  used  to  compare  proportions  between
roups (normal  weight  and  obese  children),  and  Student’s
-test and/or  Mann-Whitney  test  were  used  to  compare
uantitative measurements  between  groups.  Genotype  and
llele frequencies  for  the  polymorphism  -675  4G/5G  PAI-1
ene were  determined  by  direct  counting,  and  the  sig-
iﬁcance of  the  differences  between  the  biochemical  and
nthropometric parameters  for  each  genotype  was  deter-
ined using  ANOVA  and  by  the  Kruskal-Wallis  test;  the
hi-squared test  was  used  to  evaluate  the  Hardy-Weinberg
quilibrium. To  evaluate  the  effect  of  polymorphism,  linear
egression models  were  used.  Differences  were  considered
tatistically signiﬁcant  when  p  <  0.05.
esults
he  comparison  of  the  clinical  and  anthropometric  varia-
les between  both  groups  revealed,  in  the  obese  group,  a
igniﬁcant increase  of  glucose  and  insulin  levels,  measures
f central  and  peripheral  adiposity,  as  well  as  systolic  and
iastolic blood  pressures.  The  prevalence  of  insulin  resis-
ance the  in  obese  group  was  49.41%,  versus  the  16.85%  of
he group  with  normal-weight  (Table  1).
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Table  1  Clinical  and  biochemical  characteristics  in  normal  weight  and  obese  children.
Variables  Normal  weight  children  (n  =  89)  Obese  children  (n  =  85)  p-value
Age  (years)a 9  (6--12)  9  (6--11)  0.66
Gender (%)b 0.12
Male 40  (44.94)  48  (56.47)
Female  49  (55.06)  37  (43.53)
Weight  (kg)a 28  (19.2--41.8)  44.2  (27.4--64.9)  <  0.001
Height (cm)c 130.9  ±  10.96 135.9 ±  11.66  <  0.05
BMI (kg/m2)a 16.3  (13.9--19.7) 23.4  (18.8--29.25) < 0.001
Waist-hip-ratioa 0.87  (0.8--0.95) 0.9 (0.8--1) < 0.001
Waist circumference  (cm)a 62  (52--73) 80 (65--94) < 0.001
Hip circumference  (cm)a 70  (61--82)  85  (68.5--100)  <  0.001
Arm circumference  (cm)a 19  (15--23)  24.5  (20.5--32)  <  0.001
Biceps skinfold  (mm)c 13.53  ±  4.03  17.84  ±  4.19  <  0.001
Triceps skinfold  (mm)a 12  (7.5--18) 18 (11.5--22) < 0.001
Subscapular skinfold  (mm)a 9.5  (5--17) 18.5  (11.5--24.5) < 0.001
Suprailiac skinfold  (mm)c 15.11  ±  4.56 21.33 ±  4.85 < 0.001
Glucose (mg/dL)a 95  (72--109) 98 (81--109) < 0.05
Insulin (U/mL)a 4.7  (0.55--13.58) 9.39  (1.25--27.53) < 0.001
HOMA-IRa 1.1  (0.12--3.12) 2.2 (0.24--6.78) < 0.001
Insulin resistancec <  0.001
Yes 15  (16.85)  42  (49.41)
No  74  (83.15)  43  (50.59)
BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; SD, standard deviation.
a Data provided as median and 5th and 95th. Mann-Whitney test.
b Data provided as n and percentage. Chi-squared test.
c Data provided as mean±SD. Student’s t-test.
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5The  4G/5G  PAI-1  polymorphism  was  found  in  Hardy  Wein-
berg equilibrium  (X2 =  0.95,  p  =  0.4).  The  distribution  of
genotype and  allele  frequencies  of  -675  4G/5G  PAI-1  poly-
morphism was  as  follows:  in  the  obese  group,  8.24%  4G/4G,
49.41% 4G/5G  and  42.35%  5G/5G,  for  4G  allele  32.94%  and
5G allele  67.06%,  whereas  in  the  normal-weight  group,  8.99%
4G/4G, 34.83%  4G/5G  and  56.18%  5G/5G,  for  4G  allele
26.40% and  5G  allele  73.60%.  In  both  groups,  the  5G/5G
genotype and  the  5G  allele  were  the  most  frequently  iden-
tiﬁed. The  comparison  between  both  groups  showed  no
signiﬁcant differences  in  genotype  (2 =  3.91,  p  =  0.14)  and
allele frequencies  (2 =  1.78,  p  =  0.18).
Clinical and  biochemical  variables  were  compared  by
genotypes of  -675  4G/5G  polymorphism.  Carriers  of  the
4G/5G genotype  showed  a  signiﬁcant  increase  in  waist-hip
ratio (p  =  0.02),  and  trends  for  the  increase  in  waist  cir-
cumference (p  =  0.08)  and  subscapular  skinfold  thickness
(p =  0.09)  compared  with  carriers  of  genotypes  4G/4G  and
5G/5G (Table  2).
To estimate  the  contribution  of  polymorphism  to  anthro-
pometric and  metabolic  variables,  multiple  linear  regression
models were  used.  After  adjustment  for  age  and  gender,  it
was determined  that  the  4G/5G  genotype  contributed  to  a
signiﬁcant increase  in  waist-hip  ratio  (  =  0.02,  p  =  0.006),
waist circumference  (  =  4.42,  p  =  0.009),  and  subscapular
skinfold thickness  (  =  1.79,  p  =  0.04)  (Table  3).  However,  no
relationship with  insulin  levels,  HOMA-IR,  or  insulin  resis-
tance was  found  (data  not  shown).
g
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t  is  currently  known  that  insulin  resistance  is  an  impor-
ant predictor  of  diabetes  mellitus  type  2,  and  is  one  of  the
ain factors  involved  in  the  development  of  insulin  resis-
ance related  to  increased  adipose  tissue  and  its  release  of
dipocytokines; a  protein  that  is  secreted  by  adipocytes  in
reat amounts  is  PAI-1.13 Previous  studies  in  other  popula-
ions to  investigate  the  contribution  of  PAI-1  polymorphism
ith obesity  and  insulin  resistance  have  reported  inconsis-
ent results.14 In  the  present  study,  it  was  found  that  the
675 4G/5G  polymorphism  is  related  with  measures  of  body
diposity, but  not  with  insulin  resistance,  in  Mexican  chil-
ren.
The results  indicate  that  this  sample  of  obese  children
ad increased  glucose  and  insulin  levels,  measures  of  cen-
ral and  peripheral  adiposity,  and  a  high  prevalence  of  insulin
esistance (49.41%);  however,  16.85%  of  normal-weight  chil-
ren had  insulin  resistance.
Regarding the  genotype  and  allele  frequency,  it  was
bserved that  this  polymorphism  is  inversely  distributed
ompared to  those  reported  in  white  populations,  in  which
he 4G/4G  genotype  (>  25%)  was  more  common  than  the
G/5G genotype.  In  the  present  population,  the  5G/5G
enotype was  more  frequent  (42.35%),  and  the  4G/4G  geno-
ype was  less  common  (8.24%).  These  differences  can  be
ttributed to  the  racial  inﬂuence,  which  may  be  related
o the  genetic  background  of  the  population.  It  is  known
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Table  2  Clinical  and  biochemical  characteristics  stratiﬁed  by  -675  4G/5G  polymorphism  in  the  PAI-1  gene.
Variables  4G/4G  (n  =  18)  4G/5G  (n  =  70)  5G/5G  (n  =  86)  p-value
Age  (years)a 9  (6--13)  9  (6--12)  9  (6--11)  0.74
Gender (%)b 0.39
Male 10  (55.56)  31  (44.29)  47  (54.65)
Female 8  (44.44)  39  (55.71)  39  (45.35)
Weight (kg)a 31.85  (19.2--62.4)  37.75  (19.7--59.2)  32.1  (21--59.1)  0.24
Height (cm)c 131.92  ±  10.56 133.7  ±  12.53  133.39  ±  11  0.45
BMI (kg/m2)a 17.75  (13.81--28.4) 20.5  (14.4--28.2) 17.5  (14.9--27.5)  0.22
Waist-hip-ratioa 0.88  (0.77--1.08) 0.9  (0.8--1) 0.89  (0.8--0.97) 0.02
Waist circumference  (cm)a 65  (55--89) 71.5  (56--90) 66.75  (53--90) 0.08
Hip circumference  (cm)a 74.5  (62--100)  80  (61--99)  74.5  (63--96)  0.27
Arm circumference  (cm)a 21  (15--32)  23  (16--39)  20.5  (17--28)  0.13
Biceps skinfold  (mm)c 16.36  ±  4.76  16.07  ±  4.70  15.13  ±  4.55  0.94
Triceps skinfold  (mm)a 15.25  (9--28.5) 16  (8.5--21.5) 14  (8--21.5)  0.3
Subscapular skinfold  (mm)a 11  (5--26) 16  (6--22.5) 12.5  (6--22) 0.09
Suprailiac skinfold  (mm)c 18.14  ±  6.24 18.58  ±  5.09 17.80  ±  5.96 0.32
Glucose  (mg/dL)a 97.5  (81--118) 95  (70--111) 97  (75--107) 0.32
Insulin (U/mL)a 4.6  (0.55--53.58) 8.4  (0.79--22.1) 6.25  (1.72--24.97) 0.09
HOMA-IRa 1.12  (0.11--12.83) 1.95  (0.19--4.88) 1.42  (0.33--6.04) 0.16
Insulin resistanceb 0.24
Yes 5  (27.78)  28  (40)  24  (27.91)
No 13  (72.22)  42  (60)  62  (72.09)
BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; PAI-1, plasminogen activator inhibitor 1; SD,
standard deviation.
a Data provided as median and 5th and 95th percentiles. Kruskal-Wallis test.
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hat  the  Mexican  population  originated  from  a  mixture  of
uropean and  African  populations  with  Amerindian  groups,
iving origin  to  the  Mexican  mestizo  population,  which  has
 great  genetic  diversity  in  the  distribution  of  this  and  other
olymorphisms.15 This  can  explain  the  differences  in  the  dis-
ribution of  both  genotypic  and  allelic  frequencies  of  this
opulation with  other  populations  in  the  world.  The  fre-
uencies reported  in  the  present  study  are  consistent  with
hose reported  in  a  previous  study  in  a  mestizo  population
f western  Mexico,  where  a  high  frequency  of  5G  allele  was
bserved.16 Similarly,  in  ethnic  groups  of  Mexico,  the  5G
llele is  predominant  (≥  50%)  compared  with  the  4G  allele,17
hich  suggests  that  the  high  frequency  of  5G  allele  may  be
ue to  the  contribution  of  Amerindian  genes  in  the  genetic
ackground of  the  Mexican  population.
This  study  described,  for  ﬁrst  time  in  Mexican  children,
hat -675  4G/5G  polymorphism  in  the  PAI-1  gene  is  not
i
o
p
o
Table  3  Effect  of  -675  4G/5G  polymorphism  on  body  measures.
Variable  Model  without  adjuste
  (CI  95%)  R2
Genotypes  4G/5G  vs  5G/5G
Waist-hip-ratio 0.02 (0.004--0.04) 0.03  
Waist  circumference  (cm) 3.74 (0.09--7.39)  0.02  
Subscapular  skinfold  (mm)  1.81  (0.71--3.54)  0.02  
a Adjusted by age and gender. 95% CI, 95% conﬁdence interval.ssociated  with  insulin  resistance,  but  with  increased  body
diposity, determined  by  increase  in  the  waist-hip  ratio,
aist circumference,  and  subscapular  skinfold  thickness,
n carriers  of  4G/5G  genotype.  In  contrast,  some  authors
ave reported  a  relationship  between  the  4G/4G  genotype
ith insulin  resistance  and  increased  adipose  tissue  in  white
opulations,14 where  the  4G  allele  is  considered  the  risk
llele, since  it  was  associated  with  high  plasma  levels  of
AI-1 due  to  the  lack  of  a  binding  site  for  a  transcriptional
epressor gene.11,18
It  is  well  known  that  obese  adults  and  children  have
igher plasma  levels  of  PAI-1  than  non-obese  controls.
ther studies  have  shown  that  high  BMI,  dyslipidemia,  andnsulin resistance  are  associated  with  high  PAI-1  levels  in
bese adults.14,19--22 This  is  possibly  because  adipose  tissue
roduces PAI-1,  and  increases  circulating  PAI-1  levels  in  both
bese and  insulin-resistant  subjects.  Furthermore,  studies  of
d  Model  adjusteda
p-value    (CI  95%)  R2 p-value
0.01  0.02  (0.006--0.04)  0.11  0.006
0.04  4.42  (1.09--7.74)  0.21  0.009
0.04  1.79  (0.06--3.52)  0.05  0.04
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2Body  adiposity  and  PAI-1  gene  
PAI-1  knockout  mice  have  shown  an  effect  of  PAI-1  on  weight
gain and  increased  adipose  cellularity  associated  with  high-
fat  die.23 Besides  disruption  of  the  PAI-1  gene  reducing  the
adiposity of  the  obese  ob/ob  mice,  this  suggests  that  the
PAI-1 gene  can  control  fat  mass.  Although  the  mechanism  of
action is  not  yet  known,  it  has  been  proposed  that  the  pro-
liferation of  adipocytes  may  be  related  to  the  expression  of
genes, such  as  tumor  necrosis  factor  alpha  (TNF-),  trans-
forming growth  factor  beta  (TGF-),  leptin,  and  insulin.24
In  the  present  study,  the  -675  4G/5G  polymorphism  in  the
PAI-1 gene  was  associated  with  increased  body  adiposity,  and
not with  insulin  resistance.  This  is  probably  because  the  -675
4G/5G polymorphism  in  the  PAI-1  gene  does  not  contribute
directly to  the  development  of  insulin  resistance  in  normal-
weight and  obese  children;  as  the  insulin  resistance  may  be
of multifactorial  origin,  in  which  environmental  and  genetic
factors are  involved.  That  could  be  inﬂuenced  by  other  poly-
morphisms related  to  alterations  in  energetic  metabolism,
and to  the  development  of  obesity  in  children.  Although
the data  suggest  that  the  -675  4G/5G  polymorphism  in  PAI-1
gene is  linked  to  body  adiposity,  further  studies  are  needed
to clarify  this  role.
Even though  in  this  study  an  association  between  geno-
type 4G/5G  polymorphism  in  the  PAI-1  gene  and  body
adiposity was  found,  a  limitation  of  the  present  study  is  that
PAI-1 plasma  levels  were  not  measured;  thus,  the  association
of the  genotypes  with  PAI-1  levels  remains  uncertain  in  this
population. Future  studies  in  Mexican  children  are  necessary
to determine  this  parameter.
In  summary,  the  -675  4G/5G  genotype  of  the  PAI-1  gene
was associated  with  measures  of  body  adiposity  but  not  with
insulin resistance,  which  suggests  that  this  genotype  may
confer susceptibility  for  obesity  in  Mexican  children.
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